Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
Washington University School of Medicine
City of Hope Medical Center
Children's Oncology Group
Endeavor Biomedicines, Inc.
Emory University
Eli Lilly and Company
Milton S. Hershey Medical Center
Children's Oncology Group
Medical University of Vienna
National Institutes of Health Clinical Center (CC)
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
Nationwide Children's Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Pediatric Brain Tumor Consortium
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Stanford University
Children's Oncology Group
The Hospital for Sick Children
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
University of California, San Francisco
Augusta University
National Institutes of Health Clinical Center (CC)
Augusta University
The University of Texas Health Science Center, Houston
Hoffmann-La Roche